Showing results (81-90 of 446) with videos related to
Sort By:
Pageof 45
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSDAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 10, 2021
Optic Neuritis-Independent Retinal Atrophy in Neuromyelitis Optica Spectrum DisorderAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.Plos One|August 20, 2011
The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trialsChristina V Warner, Stephanie B Syc, Aleksandra M Stankiewicz, et al.Cell|August 18, 2023
The calvaria stands alone: Unique aspects of the skull bone marrow-meninges borderSachin P Gadani, Peter A CalabresiCNS Drugs|December 29, 2011
PEGylation of interferon-β-1a: a promising strategy in multiple sclerosisBernd C Kieseier, Peter A CalabresiNeurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.Journal of the Neurological Sciences|October 3, 2012
Objective characterization of the relative afferent pupillary defect in MSPaul Blazek, Scott L Davis, Benjamin M Greenberg, et al.Annals of Indian Academy of Neurology|February 26, 2010
Promising treatments of tomorrow for multiple sclerosisDaniel M Harrison, Peter A CalabresiSeminars in Neurology|February 8, 2008
Future research directions in multiple sclerosis therapiesBenjamin M Greenberg, Peter A CalabresiJournal of Neuroimmunology|January 1, 2017
Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosisEliza Gordon-Lipkin, Peter A CalabresiPageof 45